<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article207</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/STOPAH" style="display:block; margin-bottom:10px;">STOPAH Original</a></li>
<h2><strong>STOPAH</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>
<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does pentoxifylline or prednisolone improve survival rates in patients with severe alcoholic hepatitis?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Pentoxifylline did not improve survival rates in patients with alcoholic hepatitis. Prednisolone was associated with a reduction in 28-day mortality that did not reach significance and with no improvement in outcomes at 90 days or 1 year.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, double-blind, randomized controlled trial with a 2-by-2 factorial design evaluating pentoxifylline and prednisolone as treatments.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- 1,103 patients were enrolled initially, with 1,053 available for the final analysis.<br/>
- Inclusion criteria:<br/>
  - Age ≥18 years<br/>
  - Clinical diagnosis of alcoholic hepatitis<br/>
  - Severe disease (discriminant function ≥32 or bilirubin &gt;80 μmol/L)<br/>
  - History of heavy and prolonged alcohol use<br/>
- Exclusion criteria:<br/>
  - Jaundice for more than 3 months<br/>
  - Cessation of alcohol consumption for more than 2 months prior to randomization <br/>
  - Other causes of liver disease present<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Patients were randomized into four groups:<br/>
  - Placebo for both pentoxifylline and prednisolone<br/>
  - Prednisolone alone<br/>
  - Pentoxifylline alone<br/>
  - Both prednisolone and pentoxifylline<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome:<br/>
- Mortality at 28 days:<br/>
  - Placebo–placebo: 17%<br/>
  - Prednisolone–placebo: 14%<br/>
  - Pentoxifylline–placebo: 19%<br/>
  - Prednisolone–pentoxifylline: 13%<br/>
<br/>
Secondary Outcomes:<br/>
- Death or liver transplantation at 90 days and at 1 year, with no significant differences observed between groups.<br/>
- Serious infections occurred in 13% of prednisolone patients versus 7% who did not receive prednisolone (P=0.002).<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
The accuracy of diagnosing alcoholic hepatitis without liver biopsy could be questioned, potentially impacting the power of the study to detect a treatment effect. The study was stopped early due to funding limitations, limiting the follow-up data available for some participants.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Funded by the National Institute for Health Research Health Technology Assessment program.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Original publication in The New England Journal of Medicine, "Steroids or Pentoxifylline for Alcoholic Hepatitis", 2015.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
